DICP OpenIR
学科主题物理化学
Time Dependent Inhibition Of CYP3A4 Was The Potent Reason For High-Frequency Clinical Drug-Drug Interaction Of Erlotinib
Dong PP(董佩佩); Fang ZZ(房中则); Zhang YY(张延延); Ge GB(葛广波); Mao YX(毛玉玺); Zhu LL(朱亮亮); Li W(李巍); Yang L(杨凌); Ling Yang
会议名称18th International Symposium on Microsomes and Drug Oxidations
会议日期2010-5-16
2010-05-16
会议地点中国
页码259/1
部门归属十八室
主办者Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College
英文摘要Background: To expain the high frenquency drug-drug interactions of erlotinib, the inhibition potential and kinetic information of erlotinib to seven CYP isoforms was investigated. Meanwhile the in vivo drug-drug interaction magnitude was extrapolated from in vitro data. The activities of seven CYP isoforms (CYP3A4, CYP1A2, CYP2A6, CYP2E1, CYP2D6, CYP2C9, CYP2C8) in human liver microsomes were investigated following co- or pre-incubation with erlotinib. A two-step incubation method was used to examine in vitro TDI of erlotinib. Reversible and TDI prediction equations were employed to extrapolate in vivo drug-drug interaction magnitude from in vitro data. Results: Among seven CYP isoforms tested, the activities of CYP3A4 and CYP2C8 were inhibited with an IC50 of 31.8±7.7 μM and 6.17±1.8 μM. Kinetic analysis showed that inhibition of CYP3A4 and CYP2C8 by erlotinib was best fit to a competitive manner with Ki value of 20.8 μM and 6.2μM. Erlotinib also exhibited TDI to CYP3A4. The inactivation parameters (KI and kinact) were calculated to be 19.0 μM and 0.18 min-1. For three different doses of erlotinib (50,100,150 mg/day), the AUC of coadministered drugs was predicted to increase 0.8%, 0.9% and 1.5% using unbound portal vein concentration with reversible inhibition prediction equation for CYP3A4. As for CYP2C8, the increasement of AUC was predicted to be 2.7%, 3.2% and 5.3%. With TDI prediction equation for three different doses for CYP3A4, the AUC was estimated to increase by 8.98~467.5%, 9.9~868.1% and 10.2~1268.0 using unbound systemic concentration for fm from 0.1 to 1 separately. Conclusions: TDI of erlotinib potentially explains the high-frequency clinical drug-drug interaction of erlotinib. Attentions should be payed when the drugs which are mainly cleared by CYP3A4 were coadminstered with erlotinib.
语种中文
文献类型会议论文
条目标识符http://cas-ir.dicp.ac.cn/handle/321008/114062
专题中国科学院大连化学物理研究所
通讯作者Ling Yang
推荐引用方式
GB/T 7714
Dong PP,Fang ZZ,Zhang YY,et al. Time Dependent Inhibition Of CYP3A4 Was The Potent Reason For High-Frequency Clinical Drug-Drug Interaction Of Erlotinib[C],2010:259/1.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[董佩佩]的文章
[房中则]的文章
[张延延]的文章
百度学术
百度学术中相似的文章
[董佩佩]的文章
[房中则]的文章
[张延延]的文章
必应学术
必应学术中相似的文章
[董佩佩]的文章
[房中则]的文章
[张延延]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。